CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Lisata Therapeutics, Inc - LSTA CFD

    2.44
    5.43%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.18
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 0.01
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 2.58
    Open* 2.51
    1-Year Change* -19.81%
    Day's Range* 2.38 - 2.62
    52 wk Range 0.40-1.26
    Average Volume (10 days) 131.69K
    Average Volume (3 months) 2.95M
    Market Cap 30.92M
    P/E Ratio -100.00K
    Shares Outstanding 60.58M
    Revenue N/A
    EPS -0.41
    Dividend (Yield %) N/A
    Beta 0.91
    Next Earnings Date Nov 2, 2022

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 7, 2023 2.58 0.49 23.44% 2.09 2.69 2.09
    Dec 6, 2023 2.44 0.29 13.49% 2.15 2.57 2.09
    Dec 5, 2023 2.19 -0.07 -3.10% 2.26 2.29 2.11
    Dec 4, 2023 2.25 0.14 6.64% 2.11 2.25 2.07
    Dec 1, 2023 2.14 0.06 2.88% 2.08 2.14 2.08
    Nov 30, 2023 2.17 -0.17 -7.26% 2.34 2.38 2.06
    Nov 29, 2023 2.43 0.04 1.67% 2.39 2.43 2.22
    Nov 28, 2023 2.39 0.06 2.58% 2.33 2.41 2.24
    Nov 27, 2023 2.41 -0.03 -1.23% 2.44 2.48 2.39
    Nov 24, 2023 2.29 0.05 2.23% 2.24 2.43 2.24
    Nov 22, 2023 2.24 0.15 7.18% 2.09 2.24 2.04
    Nov 21, 2023 2.16 0.07 3.35% 2.09 2.21 2.09
    Nov 20, 2023 2.19 0.00 0.00% 2.19 2.20 2.09
    Nov 17, 2023 2.23 0.03 1.36% 2.20 2.26 2.19
    Nov 16, 2023 2.24 0.05 2.28% 2.19 2.25 2.19
    Nov 15, 2023 2.23 0.01 0.45% 2.22 2.24 2.14
    Nov 14, 2023 2.22 0.13 6.22% 2.09 2.24 2.09
    Nov 13, 2023 2.12 0.03 1.44% 2.09 2.13 2.09
    Nov 10, 2023 2.13 0.00 0.00% 2.13 2.20 2.06
    Nov 9, 2023 2.09 -0.08 -3.69% 2.17 2.22 2.02

    Lisata Therapeutics, Inc Events

    Time (UTC) Country Event
    Thursday, March 28, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q4 2023 Lisata Therapeutics Inc Earnings Release
    Q4 2023 Lisata Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total revenue 0 0 0 0 0
    Total Operating Expense 29.05 19.145 20.092 16.987 27.593
    Selling/General/Admin. Expenses, Total 11.37 9.892 9.295 9.393 11.7501
    Research & Development 17.68 9.253 10.797 7.594 15.843
    Operating Income -29.05 -19.145 -20.092 -16.987 -27.593
    Interest Income (Expense), Net Non-Operating 0.151 0 -0.005 -0.37777
    Other, Net -0.075 0.132 0.74 0.824 0.2731
    Net Income Before Taxes -28.974 -19.013 -19.352 -16.168 -27.6977
    Net Income After Taxes -27.466 -8.141 -19.352 -16.168 -16.1712
    Minority Interest 0 -0.009 -0.009 0.001 0.18246
    Net Income Before Extra. Items -27.466 -8.15 -19.361 -16.167 -15.9887
    Total Extraordinary Items 0 38.9674
    Net Income -27.466 -8.15 -19.361 -16.167 22.9787
    Income Available to Common Excl. Extra. Items -27.466 -8.15 -19.361 -16.167 -15.9887
    Income Available to Common Incl. Extra. Items -27.466 -8.15 -19.361 -16.167 22.9787
    Diluted Net Income -27.466 -8.15 -19.361 -16.167 22.9787
    Diluted Weighted Average Shares 55.313 15.44 10.325 9.689 8.96895
    Diluted EPS Excluding Extraordinary Items -0.49656 -0.52785 -1.87516 -1.66859 -1.78267
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -0.49656 -0.52785 -1.87516 -1.66859 -1.78267
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total revenue 0 0 0 0 0
    Total Operating Expense 6.62 6.849 6.968 7.147 8.086
    Selling/General/Admin. Expenses, Total 3.342 2.699 2.843 2.818 3.01
    Research & Development 3.278 4.15 4.125 4.329 5.076
    Operating Income -6.62 -6.849 -6.968 -7.147 -8.086
    Interest Income (Expense), Net Non-Operating 0.063 0.04 0.041 0.047 0.023
    Net Income Before Taxes -6.705 -6.794 -6.927 -7.19 -8.063
    Net Income After Taxes -4.226 -6.794 -6.927 -5.682 -8.063
    Minority Interest 0 0 0 0 0
    Net Income Before Extra. Items -4.226 -6.794 -6.927 -5.682 -8.063
    Net Income -4.226 -6.794 -6.927 -5.682 -8.063
    Income Available to Common Excl. Extra. Items -4.226 -6.794 -6.927 -5.682 -8.063
    Income Available to Common Incl. Extra. Items -4.226 -6.794 -6.927 -5.682 -8.063
    Diluted Net Income -4.226 -6.794 -6.927 -5.682 -8.063
    Diluted Weighted Average Shares 60.56 59.819 59.614 59.51 42.117
    Diluted EPS Excluding Extraordinary Items -0.06978 -0.11358 -0.1162 -0.09548 -0.19144
    Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
    Diluted Normalized EPS -0.06978 -0.11358 -0.1162 -0.09548 -0.19144
    Other, Net -0.148 0.015 0 -0.09
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 96.182 35.331 25.972 44.106 61.397
    Cash and Short Term Investments 94.97 34.573 25.157 43.053 55.08
    Cash & Equivalents 24.647 16.512 14.032 10.299 29.163
    Short Term Investments 70.323 18.061 11.125 32.754 25.917
    Total Receivables, Net
    Accounts Receivable - Trade, Net
    Prepaid Expenses 1.212 0.758 0.815 1.053 1.312
    Other Current Assets, Total 0 5.005
    Total Assets 97.008 36.002 27.153 44.58 63.376
    Property/Plant/Equipment, Total - Net 0.786 0.631 1.006 0.165 0.257
    Other Long Term Assets, Total 0.04 0.04 0.175 0.309 1.722
    Total Current Liabilities 4.523 3.506 5.976 5.619 9.314
    Accounts Payable 1.934 1.02 1.49 0.762 1.343
    Accrued Expenses 2.589 2.486 4.486 4.857 7.812
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.159
    Other Current Liabilities, Total
    Total Liabilities 4.754 3.506 6.337 6.854 12.869
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Minority Interest -0.254 -0.254 -0.263 -0.272 -0.318
    Other Liabilities, Total 0.485 0.254 0.624 1.507 3.873
    Total Equity 92.254 32.496 20.816 37.726 50.507
    Common Stock 0.06 0.019 0.011 0.01 0.009
    Additional Paid-In Capital 545.988 458.748 438.911 436.433 433.044
    Retained Earnings (Accumulated Deficit) -453.016 -425.55 -417.4 -397.977 -381.81
    Treasury Stock - Common -0.708 -0.708 -0.708 -0.708 -0.708
    Other Equity, Total -0.07 -0.013 0.002 -0.032 -0.028
    Total Liabilities & Shareholders’ Equity 97.008 36.002 27.153 44.58 63.376
    Total Common Shares Outstanding 59.7897 19.3783 10.5176 9.85466 9.47283
    Total Preferred Shares Outstanding 0.01 0.01 0.01 0.01 0.01
    Property/Plant/Equipment, Total - Gross 1.154 0.944 1.255
    Accumulated Depreciation, Total -0.368 -0.313 -0.249
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 90.7 96.182 102.107 108.08 114.033
    Cash and Short Term Investments 88.519 94.97 100.149 106.09 111.511
    Cash & Equivalents 12.747 24.647 12.772 12.935 28.744
    Short Term Investments 75.772 70.323 87.377 93.155 82.767
    Prepaid Expenses 2.181 1.212 1.958 1.99 2.522
    Total Assets 91.463 97.008 102.538 108.614 114.607
    Property/Plant/Equipment, Total - Net 0.722 0.786 0.392 0.492 0.533
    Other Long Term Assets, Total 0.041 0.04 0.039 0.042 0.041
    Total Current Liabilities 2.801 4.523 4.072 3.856 4.438
    Accounts Payable 0.697 1.934 0.768 1.242 2.315
    Accrued Expenses 2.104 2.589 3.304 2.614 2.123
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 2.968 4.754 3.871 3.681 4.339
    Total Long Term Debt 0 0 0 0 0
    Minority Interest -0.254 -0.254 -0.254 -0.254 -0.254
    Other Liabilities, Total 0.421 0.485 0.053 0.079 0.155
    Total Equity 88.495 92.254 98.667 104.933 110.268
    Common Stock 0.061 0.06 0.06 0.06 0.06
    Additional Paid-In Capital 546.58 545.988 545.601 544.893 544.601
    Retained Earnings (Accumulated Deficit) -457.242 -453.016 -446.222 -439.295 -433.613
    Treasury Stock - Common -0.708 -0.708 -0.708 -0.708 -0.708
    Other Equity, Total -0.196 -0.07 -0.064 -0.017 -0.072
    Total Liabilities & Shareholders’ Equity 91.463 97.008 102.538 108.614 114.607
    Total Common Shares Outstanding 60.5331 59.7897 59.7799 59.5175 59.499
    Total Preferred Shares Outstanding 0.01 0.01 0.01 0.01 0.01
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line -27.466 -8.141 -19.352 -16.168 22.2281
    Cash From Operating Activities -22.245 -8.823 -18.882 -19.986 -20.8759
    Cash From Operating Activities 0.055 0.063 0.065 0.225 0.372
    Deferred Taxes 0 -12.1016
    Non-Cash Items 4.519 1.572 1.527 1.306 -36.5223
    Cash Taxes Paid 0 0 0 0 0
    Cash Interest Paid 0 0 0 0.005 0.7119
    Changes in Working Capital 0.647 -2.317 -1.122 -5.349 5.14797
    Cash From Investing Activities -54.896 -7.277 21.432 -4.707 41.2706
    Capital Expenditures -0.06 -0.02 0 -0.134 -0.13528
    Other Investing Cash Flow Items, Total -54.836 -7.257 21.432 -4.573 41.4059
    Cash From Financing Activities 85.276 18.58 1.183 0.824 -0.93177
    Financing Cash Flow Items -0.248 -0.148 -0.13 -0.403 -0.4319
    Issuance (Retirement) of Stock, Net 85.524 18.728 1.313 1.386 5.71526
    Issuance (Retirement) of Debt, Net 0 -0.159 -6.21513
    Net Change in Cash 8.135 2.48 3.733 -23.869 19.463
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -4.226 -27.466 -20.672 -13.745 -8.063
    Cash From Operating Activities -5.642 -22.245 -17.641 -12.602 -7.975
    Cash From Operating Activities 0.007 0.055 0.047 0.033 0.016
    Non-Cash Items 1.275 4.519 3.564 2 0.92
    Changes in Working Capital -2.698 0.647 -0.58 -0.89 -0.848
    Cash From Investing Activities -6.09 -54.896 -71.354 -76.294 -65.09
    Capital Expenditures -0.06 -0.06 -0.06 0
    Other Investing Cash Flow Items, Total -6.09 -54.836 -71.294 -76.234 -65.09
    Cash From Financing Activities -0.168 85.276 85.255 85.319 85.297
    Financing Cash Flow Items -0.168 -0.248 -0.248 -0.184 -0.184
    Issuance (Retirement) of Stock, Net 0 85.524 85.503 85.503 85.481
    Net Change in Cash -11.9 8.135 -3.74 -3.577 12.232

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Lisata Therapeutics, Inc Company profile

    About Caladrius Biosciences Inc

    Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

    Financial summary

    BRIEF: For the 39 weeks ended 30 September 2021, Caladrius Biosciences Inc revenues was not reported. Net loss increased from $2.7M to $20.7M. Higher net loss reflects Research and development increase from $6.1M to $12.9M (expense), Other Selling, gen & admi increase of 18% to $7.7M (expense), Stock-based Compensation in R&D increase from $239K to $643K (expense).

    Equity composition

    Common Stock $.001 Par, 03/11, 500M auth., 78,564,199 issd. reverse acquisition with Fidelity Medical Services Inc. 08/06, Name changed from Phase III Medical, Inc. 08/07, Exchange changed from OTC to AMEX. 08/07, 1-for-10 reverse stock consolidation. Pref Stock B $0.1 Par, 10,000 issd., 07/13, 1-for-10 reverse sotck split.

    Industry: Biotechnology & Medical Research (NEC)

    110 Allen Road
    Second Floor
    07920

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    BTC/USD

    44,252.10 Price
    +2.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Oil - Crude

    71.41 Price
    +2.320% 1D Chg, %
    Long position overnight fee -0.0204%
    Short position overnight fee -0.0015%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.68 Price
    +4.560% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,080.90 Price
    +0.500% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading